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Key Points
•BCL-W is dispensable
for the growth and sur-
vival of select BL- and
DLBCL-derived
cell lines.
Dysregulated expression of BCL-2 family proteins allows cancer cells to escape apoptosis.
To counter this, BH3-mimetic drugs that target and inhibit select BCL-2 prosurvival proteins
to induce apoptosis have been developed for cancer therapy. Venetoclax, which targets
BCL-2, has been effective as therapy for patients with chronic lymphocytic leukemia, and
MCL-1–targeting BH3-mimetic drugs have been extensively evaluated in preclinical
studies for a range of blood cancers. Recently, BCL-W, a relatively understudied
prosurvival member of the BCL-2 protein family, has been reported to be abnormally
upregulated in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and
Hodgkin lymphoma patient samples. Therefore, to determine if BCL-Wwould be a promising
therapeutic target for B-cell lymphomas, we have examined the role of BCL-W in the sustained
growth of human BL- and DLBCL-derived cell lines.We found that CRISPR/CAS9-mediated loss
or short hairpin RNA-mediated knockdown of BCL-W expression in selected BL and DLBCL
cell lines did not lead to spontaneous apoptosis and had no effect on their sensitivity to a range
of BH3-mimetic drugs targeting other BCL-2 prosurvival proteins. Our results suggest that
BCL-W is not universally required for the sustained growth and survival of human BL and
DLBCL cell lines. Thus, targeting BCL-W in this subset of B-cell lymphomasmaynot be of broad
therapeutic benefit.
Introduction
BCL-W (BCL2L2) was first described as a BCL-2 family protein that, upon overexpression, could
protect lymphoid and myeloid cells from apoptosis induced by cytokine deprivation and g-irradiation.1
BCL-W–deficient mice were found to be phenotypically normal, with the exception of aberrant germ cell
apoptosis in the adult testes, resulting in a lack of mature sperm.2,3 Because of the lack of overt
developmental and health defects in BCL-W–deficient mice, BCL-W is one of the least studied
members of the BCL-2 protein family. This family is characterized by the presence of 1 or more BCL-2
homology (BH) domains and includes both prosurvival and proapoptotic factors.4,5 The prosurvival
proteins (BCL-W, BCL-2, MCL-1, BCL-XL, and BFL-1/A1) are responsible for binding and restraining
the proapoptotic effectors (BAK and BAX). This prevents them from forming pores in the mitochondrial
outer membrane and thus precludes initiation of the caspase cascade that causes demolition of cells
undergoing apoptosis. The proapoptotic BH3-only proteins (BIM, BAD, BID, PUMA, BMF, BIK, HRK,
and NOXA) can bind and sequester the prosurvival BCL-2 proteins, thereby unleashing BAK and BAX
and allowing apoptosis to proceed. Additionally, certain BH3-only proteins (eg, BIM, PUMA, tBID) have
Submitted 4 June 2019; accepted 4 January 2020; published online 27 January 2020.
DOI 10.1182/bloodadvances.2019000541.
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been reported to directly activate BAX and BAK.6 The balance and
interactions between prosurvival and proapoptotic BCL-2 family
proteins within a cell determines its fate.
Defects in cell death regulation are tightly linked to tumor develop-
ment and sustained survival of malignant cells; thus, evasion of
apoptosis is a well-recognized hallmark of cancer.7 Upregulation of
prosurvival BCL-2 family members, such as via somatically acquired
amplifications of the genomic region containing theMCL-1 orBCL-X
genes found in ;10% to 15% or ;5%, respectively, of diverse
cancers,8 or loss of proapoptotic BH3-only proteins9,10 are
commonly associated with malignant diseases. Genetic experi-
ments revealed that cancer cells can display a dependence on 1
particular prosurvival BCL-2 protein for ongoing survival; multiple
myeloma and Burkitt lymphoma (BL) cells are largely reliant on
MCL-1,11,12 whereas chronic lymphocytic leukemia cells exhibit
BCL-2 dependency.13 Accordingly, the development of BH3-mimetic
drugs that can bind and inhibit specific prosurvival BCL-2 family
proteins has been an intense area of study over the past decade,14,15
culminating in dozens of clinical trials and, ultimately, US Food and
Drug Administration approval of the BCL-2 inhibitor venetoclax for
the treatment of patients with chronic lymphocytic leukemia5,16,17 and
acute myeloid leukemia.18,19 BH3-mimetic drugs targeting other
prosurvival proteins are in various stages of development. Clinical trials
commenced with MCL-1 inhibitors for certain B-cell malignancies,
acute myeloid leukemia, and multiple myeloma.20 ABT-263/navitoclax,
which targets BCL-2, BCL-XL, and BCL-W, as well as BCL-XL
specific inhibitors, such as WEHI-539, were shown to potently kill
diverse cancer-derived cell lines in culture and in vivo.21,22 However,
on-target toxicity to platelets, which rely on BCL-XL for survival, has
stalled the progression of these drugs in clinical trials.23,24
Recent reports have implicated a role for BCL-W in human cancers.
It was shown that BCL-W is significantly overexpressed in a wide
range of human B-cell lymphomas, including BL, diffuse large B-cell
lymphoma (DLBCL), and Hodgkin lymphoma (HL) patient samples
and cell lines.25-27 It has also been reported that loss of BCL-W
delays lymphoma development in the Em-Myc transgenic mouse
model of BL and, importantly, that BCL-W expression is essential
for the sustained survival of MYC-driven human BL-derived cell
lines.25 Finally, a CRISPR/CAS9 functional screen identified BCL-
W as a factor rendering a range of human adenocarcinoma-derived
cell lines resistant to BH3-mimetic drugs targeting BCL-2, MCL-1
or BCL-XL.28 Together, these studies indicate a previously un-
derappreciated role for BCL-W in cancer and identify BCL-W as
a potentially attractive anticancer drug target.
In light of these reports, we sought to independently validate a role
for BCL-W in the survival of human BL and DLBCL cell lines. In
contrast to a previous study,25 we found that BCL-W was not
uniformly expressed at high levels across the BL and DLBCL cell
lines examined. Notably, reduction of BCL-W expression using
CRISPR/CAS9 gene editing or RNA interference in a panel of
lymphoma cell lines did not sensitize them to apoptosis, even when
these cells were treated with BH3-mimetic drugs targeting other
prosurvival BCL-2 proteins.
Materials and methods
Cell culture
Ramos-BL and Raji-BL were kind gifts from Suzanne Cory, The
Walter and Eliza Hall Institute of Medical Research (originally
received fromGeorge Klein) and David Huang, TheWalter and Eliza
Hall Institute of Medical Research, respectively. The DLBCL cell
lines U2932, HT, SUDHL-4, and SUDHL-5 were obtained from
the Germany Collection of Microorganisms and Cell Cultures
(DSMZ). All cell lines were authenticated by STR profiling at the
Australian Genome Research Facility and cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS;
MilliporeSigma), 100 U/mL penicillin, and 100 mg/mL streptomycin,
and maintained at 5% CO2. HEK293T cells were cultured in
Dulbecco’s modified Eagle medium (Thermo Fisher Scientific)
supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL
streptomycin, and maintained at 10% CO2. All cell lines were
verified as mycoplasma free.
Western blotting
Total protein was extracted by lysis in radioimmunoprecipitation
assay (RIPA) buffer (50 mM Tris-HCL, 150 mM NaCl, 1% NP-40,
0.5% DOC, 0.1% sodium dodecyl sulfate) containing complete
protease inhibitor cocktail (Roche) and quantified by Bradford
assay (Bio-Rad). Between 10 mg to 25 mg of protein was run on
10% or 4% to 12% n-polyacrylamide gel electrophoresis gels
(Thermo Fisher Scientific) and then transferred onto a nitrocellulose
membrane. Membranes were blocked in phosphate-buffered saline
containing 0.1% Tween with 5% skim milk. Membranes were
incubated in primary antibodies diluted in phosphate-buffered saline
containing 0.1% Tween, 5% bovine serum albumin (MilliporeSigma)
and 0.02% sodium azide. Antibodies are detailed in supplemental
Table 1. Membranes were imaged by addition of Immobilon Forte
Western HRP Substrate (Merck) on a ChemiDoc Imaging System
(Bio-Rad). Quantification of western blots was performed using
ImageJ (US National Institutes of Health). Data were normalized to
the HSP70 loading control.
qRT-PCR
Total RNA was extracted using Trizol reagent (Thermo Fisher
Scientific) and complementary DNA was synthesized using the
SuperScript III First Strand Synthesis Kit (Thermo Fisher Scientific)
with oligo(dT)20 primers, both methods according to the manufac-
turer’s instructions. Quantitative reverse-transcription polymerase
chain reaction (qRT-PCR) analysis was performed in triplicate using
TaqMan Gene Expression Assays (Applied Biosystems) on the
ViiA7 Real-Time PCR System (Thermo Fisher Scientific), detailed in
supplemental Table 2. Data were analyzed using QuantStudio
software (Thermo Fisher Scientific). Messenger RNA (mRNA) levels
were normalized to expression of the housekeeping gene HMBS.
CRISPR/CAS9 and shRNA constructs, virus
production, and cell sorting
CRISPR/CAS9 gene editing was performed by serial infection
using a lentiviral system composed of stably expressed CAS9,
followed by doxycycline-inducible expression of single guide RNA
(sgRNA), as described elsewhere.29 A nontargeting control sgRNA
(sgNT) construct against mouse Bim exon 2 (59-GACAATTGC
AGCCTGCTGAG-39)29 and sgRNA construct targeting human
BCL-W exon 3 (sgBCL-W: 59-GGAGTTCACAGCTCTATACG-
39)30 were used. For RNA interference, an inducible short hairpin RNA
(shRNA) construct was designed by cloning of a BCL-W target
sequence (shBCL-W: 59-TGGCAGACTTTGTAGGTTATA-39)31
into the lentiviral pF1HtUTG vector, as described.32 An shRNA
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Figure 1. Characterization of select BL- and DLBCL-derived cell lines. (A) Western blotting for prosurvival proteins, proapoptotic BIM, and TP53 in human B-cell
lymphoma lines. Probing for HSP70 was used as a loading control. Note that high TP53 protein levels in unstressed cells are indicative of tumor-driving mutations in the TP53
gene. (B) Quantification of BCL-W protein expression from representative western blotting experiments, normalized to the loading control, HSP70. (C) BCL-W gene
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construct targeting rat CD8 was used as a negative control.32 For
both methods, lentivirus was produced by transient transfection
into HEK293T cells using calcium phosphate precipitation accord-
ing to published protocols.32 Infected cells were sorted for high
expression of mCherry from the Cas9 expression vector, eGFP from
the sgRNA vector, or eGFP from the shRNA vector on an Aria W
flow cytometer (Becton Dickinson).
Induction of gene editing or RNA interference
Doxycycline hyclate (MilliporeSigma; #D9891) was added to tissue
culture medium at a concentration of 1 mg/mL to induce sgRNA or
shRNA expression. Doxycycline levels were topped up every
24 hours during sgRNA or shRNA induction. Cell viability was
determined by staining with Annexin V-Alexa Fluor 647 and DAPI,
and quantified by flow cytometry on an LSR IIW flow cytometer
(Becton Dickinson). Live cells were deemed Annexin V and DAPI
double-negative. For proliferation assays, cell number was de-
termined using a Moxi Z cell counter (ORFLO).
Next-generation sequencing
DNA was extracted using the DNeasy Blood and Tissue Kit
(Qiagen) according to the manufacturer’s protocol and PCR
amplified using sgRNA-specific primers and GoTaq Green Master
Mix (Promega). PCR products were subjected to a second round of
PCR using indexing primers, pooled, purified using Ampure XP
beads (Beckman Coulter), and sequenced using the MiSeq
platform (Illumina). Reads were mapped to the human BCL-W
reference sequence using the Basic Local Alignment Search Tool
(National Center for Biotechnology Information) and the proportion
of mutations for each cell line were calculated in Microsoft Excel.
BCL-W target site primers were FWD 59-GTGACCTATGAACTC
AGGAGTCCGCAGTGGATGGAACTGGAA-39 and REV 59-CTG
AGACTTGCACATCGCAGCGCCCTGGACTTTCACTTGCT-39.
Drug treatment assays
Cells were plated in triplicate at 3 3 104 cells/well of flat-bottomed
96-well plates. ABT-199 (Active Biochem; #A-1231), ABT-737
(Active Biochem; #1002), S63845 (Active Biochem; #6044), or
A-1331852 (AbbVie, provided by G. Lessene) in dimethyl sulfoxide
(DMSO) were added to the specified concentration. Cell viability
was determined at 24 hours, as previously described. Data were
normalized to control cells treated with an equivalent amount of
DMSO (vehicle). For assays in shRNA-induced cells, drug treat-
ments were performed following 72 hours of shRNA induction in the
presence of doxycycline.
Generation of single-cell gene-edited clones
Cells with high expression of Cas9 (mCherry) and BCL-W or NT
sgRNA (eGFP) were sorted into round-bottomed 96-well plates at
1 cell per well on an Aria W flow cytometer. Twenty-four clones
were expanded, sgRNA expression was induced with doxycy-
cline, and cells were screened for disruption of BCL2L2 (encodes
BCL-W) by western blotting and sequencing as described previ-
ously. Drug treatment assays were performed as previously. For
low-serum experiments, clones were grown in RPMI-1640 medium
supplemented with 1% FBS, 100 U/mL penicillin, and 100 mg/mL
streptomycin for 72 hours before drug treatment.
Statistical analysis
GraphPad Prism software was used for statistical analyses. Two-
tailed Student t tests were performed to compare between 2 data
sets. One-way analysis of variance with Dunnett’s post hoc test
was used to compare between more than 2 samples. Error bars
represent the standard deviation (SD) of 3 independent experi-
ments unless otherwise indicated.
Results
Characterization of human B-cell lymphoma lines
Six human B-cell lymphoma-derived cell lines were analyzed for
expression of the prosurvival proteins BCL-W, BCL-2, BCL-XL,
BFL-1, and MCL-1, along with proapoptotic BIM that is frequently
epigenetically silenced in BLs,9 and the tumor suppressor TP53,
which is mutated in ;50% of human cancers.33 The selected cell
lines included the BL lines Ramos-BL and Raji-BL, which were
previously shown to be dependent on BCL-W for survival25 and the
DLBCL lines U2932 (activated B-cell subtype), SUDHL-4, SUDHL-
5, and HT (germinal center B-cell subtype). Each cell line exhibited
a unique pattern of BCL-2 family protein expression, consistent with
previous studies (Figure 1A; supplemental Figure 1A).34,35 Both BL
cell lines were found to express BCL-W at levels detectable by
western blotting; however, BCL-W protein could only be detected
in 2 of the 4 DLBCL lines, namely HT and SUDHL-5 (Figure 1B).
Transcriptional analysis for the mRNAs encoding BCL-W along
with the other BCL-2 family prosurvival proteins were overall con-
sistent with protein expression (Figure 1C; supplemental Figure 1B).
Although it has been reported that BCL-W mRNA is significantly
overexpressed in BL and DLBCL patient samples,26 we found
higher transcriptional levels of BCL2L1 (BCL-X),MCL1, and BCL2
in 5 of the 6 lymphoma cell lines tested (supplemental Figure 1B).
Of note, MCL1, which has been implicated in the sustained growth
of MYC-driven lymphomas,36 was the most highly expressed of the
prosurvival BCL-2 family members at the mRNA level in all 6 cell
lines examined.
Testing the sensitivity of B-cell lymphoma cell lines to
BH3-mimetic drugs
BH3-mimetic drugs have been developed that can individually
target and inhibit BCL-2, BCL-XL, or MCL-1, as well as some that
collectively target BCL-2, BCL-XL, and BCL-W. These compounds
are useful to interrogate the dependency of cells on the different
prosurvival BCL-2 proteins. The selected BL and DLBCL cell lines
were treated with 5 mM each of S63845 (MCL-1 inhibitor), ABT-
199/venetoclax (BCL-2 inhibitor), ABT-737 (BCL-2, BCL-XL, and
BCL-W inhibitor), A-1331852 (BCL-XL inhibitor), or combinations
Figure 1. (continued) expression measured by qRT-PCR. Data were normalized to HMBS housekeeping gene expression. (D) Flow cytometry gating strategy to determine
cell viability. Live cells were Annexin V and DAPI double-negative. (E) Sensitivity profile of each cell line to 5 mM BH3-mimetic drugs: S63845 (MCL-1 inhibitor), ABT-199
(BCL-2 inhibitor), ABT-737 (BCL-2, BCL-XL, BCL-W inhibitor), and A-1331852 (BCL-XL inhibitor). Cell viability was measured as in panel D, and normalized to a DMSO-
treated control sample. Error bars represent the SD for 3 independent experiments. Significance is indicated for comparisons to DMSO-treated control cells (1-way analysis of
variance with Dunnett’s post hoc test, *P , .05, **P , .01, ***P , .001, ****P , .0001).
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thereof. After 24 hours, cell viability was determined by staining with
Annexin V and DAPI, and flow cytometric analyses (Figure 1D-E).
Ramos-BL, Raji-BL, HT, SUDHL-4, and SUDHL-5 cells all showed
primary dependency on MCL-1, with only a minor further increase in
apoptosis when S63845 was combined with either ABT-199 or
ABT-737. U2932 cells showed dependency on BCL-2, yet the
combination treatment with S63845 and ABT-199 was more
effective than either single agent treatment alone (Student t tests,
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Figure 2. CRISPR/CAS9-mediated loss of BCL-W
does not effect the survival of select BL and DLBCL
cell lines. (A) Cell viability following doxycycline induction
of nontargeting (sgNT) or BCL-W–targeting (sgBCL-W)
sgRNAs over 96 hours. Cell viability was measured by the
proportion of cells that were Annexin V and DAPI double
negative by flow cytometry. Error bars represent the SD
for 3 independent experiments. (B) Sequencing results for
cell lines 5 days and .1 month postinduction of BCL-W
sgRNA. Bars show the proportions of reads which were
wild type, in frame indels, or frameshift in the BCL-W
gene. The number of reads for each cell line is indicated.
(C) Western blotting for prosurvival BCL-2 family mem-
bers and proapoptotic BIM in sgBCL-W and control
(sgNT) Ramos-BL and HT cells at 5 days and .1 month
post-sgRNA induction. Probing for HSP70 was used as
a loading control. (D) BCL-2 family gene expression in
sgBCL-W and sgNT control Ramos-BL and HT cells as
determined by qRT-PCR analysis. Data are normalized to
HMBS housekeeping gene expression levels and shown
relative to HMBS levels. Error bars represent the SD of
2 independent experiments. Significance is indicated
(Student t test, *P , .05).
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ABT-199 vs ABT-199/S63845: P , .05, S63845 vs ABT-199/
S63845: P, .0001). This indicated that the survival of U2932 cells
is safeguarded by both BCL-2 and MCL-1. Of particular interest,
Ramos-BL, SUDHL-4, and U2932 cells were significantly more
sensitive to ABT-737 than ABT-199 (Student t test, P , .05 for
all), perhaps suggesting a potential minor role for BCL-W in the
survival of these cell lines, although a reliance on BCL-XL is equally
possible. Despite expressing BCL-W, as detected by western
blotting, Raji-BL, HT, and SUDHL-5 cells were resistant to ABT-737
treatment, indicating no survival dependency on BCL-2, BCL-XL, or
BCL-W, even collectively. For cell lines with a 50% inhibitory
concentration (IC50) of ;5 mM or less for a specific BH3-mimetic
drug, a dose response curve was generated to calculate accurate
IC50 values (supplemental Figure 1C).
Loss of BCL-W does not affect the survival of select
human BL and DLBCL cell lines
Four of the characterized lymphoma cell lines, namely Ramos-BL,
HT, SUDHL-4, and U2932, were selected for further analysis
by CRISPR/CAS9 gene editing. SUDHL-5 cells were excluded
because they rapidly silenced expression of the Cas9 trans-
gene, and Raji-BL cells could not be infected with the Cas9
lentivirus. For 1 of the selected lines, Ramos-BL, the knockdown of
BCL-W expression by shRNA has previously been shown to induce
apoptosis in ;50% of cells (Annexin V–positive) by 48 hours.25 To
investigate the dependence of Ramos-BL cells and the selected
DLBCL lines on BCL-W for sustained survival and growth,
CRISPR/CAS9-mediated mutations were generated in BCL2L2
(henceforth referred to as BCL-W) via the nonhomologous end
joining DNA repair pathway. Cell viability wasmonitored for 96 hours
postinduction of CRISPR/CAS9 sgRNA expression by addition of
doxycycline. In all cases, cells expressing CAS9 and a sgRNA
targeting BCL-W (sgBCL-W) did not exhibit increased cell death
compared with control cells expressing CAS9 and a nontargeting
sgRNA (sgNT) to mouse Bcl2l11 (Bim) (Figure 2A). Disruption of
the BCL-W gene was confirmed by sequencing after 5 days of
sgRNA induction, which showed that for all cell lines containing
BCL-W sgRNA,.50% of the total copies of the BCL-W–encoding
gene possessed indels, primarily resulting in frameshifts (Figure 2B).
Accordingly, substantial reductions in the expression of BCL-W
protein in the Ramos-BL and HT cell lines carrying sgBCL-W were
confirmed by western blot (Figure 2C) and qRT-PCR analyses
(Figure 2D). The cell lines with reduced BCL-W expression were
subsequently maintained in culture for.1month, alongside parental
and sgNT control cells. No effects on cell viability or cell growth
were observed for any of the 4 lymphoma lines. Sequencing of
the targeted region of BCL-W was repeated .1 month after
sgRNA induction, with all 4 cell lines now showing almost complete
mutation of the BCL-W gene (.87%) within the population.
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Figure 3. Loss of BCL-W does not sensitize BL or
DLBCL cell lines to BH3-mimetic drugs. Viability of
BCL-W–disrupted (sgBCL-W) and control (sgNT) cells
following treatment with indicated dose of BH3-mimetic
drugs for 24 hours: S63845 (MCL-1 inhibitor), ABT-199
(BCL-2 inhibitor), ABT-737 (BCL-2/BCL-XL/BCL-W
inhibitor), and A-1331852 (BCL-XL inhibitor). Cell viability
was measured by the proportion of cells that were Annexin
V and DAPI double-negative by flow cytometry, and results
were normalized to a DMSO-treated control sample. Loss
of BCL-W did not sensitize any cell lines to any of the
BH3-mimetic drugs tested (Student t test, P . .05 for all).
Error bars represent the SD for 3 independent experi-
ments. Significance is indicated (Student t test, *P , .05).
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Figure 4. shRNA-mediated knockdown of BCL-W expression does not induce apoptosis of B-lymphoma cells and does not sensitize them to BH3-mimetic
drugs targeting other prosurvival BCL-2 proteins. (A) shRNA knockdown of BCL-W was confirmed by western blotting in cell lines containing nontargeting control
(shNT) and BCL-W–targeting (shBCL-W) shRNAs. Probing for HSP70 was used as a loading control. (B) Cell viability following doxycycline induction of shNT or shBCL-W
expression over 96 hours. Cell viability was measured by the proportion of cells that were Annexin V and DAPI double-negative by flow cytometry. Error bars represent the
362 DIEPSTRATEN et al 28 JANUARY 2020 x VOLUME 4, NUMBER 2
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/2/356/1632656/advancesadv2019000541.pdf by U
N
IVER
SITY O
F BIR
M
IN
G
H
AM
 -U
SD
 AC
C
O
U
N
T user on 28 February 2020
Thus, no selection against the silencing of BCL-W was apparent.
To further confirm that BCL-W is dispensable for the survival of
these cells, we generated single-cell clones of HT cells that had
been transduced with either sgNT or sgBCL-W (supplemental
Figure 2A-B). Several of the latter clones displayed no detect-
able BCL-W protein expression, as assessed by western blotting,
and DNA sequencing revealed 100% loss of wild-type BCL-W
gene sequences in all 6 HT clones tested, validating them as total
BCL-W knockouts. As determined for the bulk populations, no cell
death was observed upon loss of BCL-W in the HT-derived cell
clones. These data indicate that BCL-W expression is not ubiqui-
tously required for the sustained survival or growth of human BL
or DLBCL cell lines, even for those that express detectable levels
of BCL-W protein.
A potential explanation for the lack of cell death observed upon
reduction or loss of BCL-W in DLBCLs and BLs is compensatory
upregulation of an alternative prosurvival BCL-2 family member or
downregulation of a proapoptotic BCL-2 family protein. To inves-
tigate this, bulk populations of gene-edited cells exhibiting loss of
BCL-W and control cells with NT sgRNA were analyzed for
prosurvival BCL-2, BCL-XL, MCL-1, and proapoptotic BIM protein
expression after 5 days of sgRNA induction (Figure 2C). In all cases,
no differences in expression of these proteins were observed
between BCL-W–disrupted cells and control cells. Moreover,
qRT-PCR analysis showed no significant differences in the mRNA
levels of the nontargeted prosurvival BCL-2 family members in HT
and Ramos-BL cells following disruption of BCL-W expression
(Figure 2D).
Loss of BCL-W does not increase the susceptibility of
human B-cell lymphoma-derived cell lines to
BH3-mimetic drugs
Knockdown of BCL-W protein levels through the enforced
expression of regulatory microRNAs has been reported to sensitize
a range of human cancer-derived cell lines to chemotherapy,
including non-small-cell and small-cell lung cancers, hepatocellular
carcinoma, and clear cell renal cell carcinoma.37-40 BCL-W has also
recently been identified in a CRISPR/CAS9 screen for factors
rendering adenocarcinoma-derived cell lines resistant to combina-
tions of BH3-mimetic drugs targeting BCL-2, MCL-1 or BCL-XL.28
Therefore, to determine whether loss of BCL-W sensitizes BL
or DLBCL cells to BH3-mimetic drugs, we treated the bulk
populations of sgNT (control) and sgBCL-W gene-edited Ramos-
BL, HT, SUDHL-4, and U2932 cells with S63845 (MCL-1 inhibitor;
note different doses were used depending upon the cell line), ABT-
199 (BCL-2 inhibitor), ABT-737 (BCL-2/BCL-W/BCL-XL inhibitor),
or A-1331852 (BCL-XL inhibitor). In all cases, the reduction of
BCL-W protein did not significantly increase sensitivity of these
particular lymphoma cell lines to any of the tested BH3-mimetic
drugs following 24 hours of treatment (Figure 3). Furthermore,
treatment of the HT BCL-W knockout clones gave results that were
consistent with the analyses of the bulk cell populations, with no
differences in sensitivity observed between BCL-W–deficient and
control clones (supplemental Figure 2C-D). This was even the case
when BCL-W-deficient clones were stressed by preculture in low-
serum conditions (supplemental Figure 2E). These results indicate
that BCL-W loss does not sensitize these B-cell lymphoma cells to
BH3-mimetic drugs that target other BCL-2 prosurvival proteins.
shRNA-mediated knockdown of BCL-W has no effect
on survival or proliferation of select human BL- and
DLBCL-derived cell lines
We sought to validate the finding that CRISPR/CAS9-mediated
disruption of BCL-W expression had no effect on survival of the
B-cell lymphoma cell lines using shRNA-mediated reduction of
BCL-W expression. For these experiments, we selected the BL cell
lines Raji-BL and Ramos-BL as shRNA-mediated knockdown of
BCL-W has been shown to induce apoptosis in these cell lines,25
and the DLBCL cell line HT, which was found to express the
highest levels of BCL-W of our cell line panel by western blotting.
These cell lines were infected with lentiviral vectors containing
doxycycline-inducible shRNAs against BCL-W (shBCL-W) or rat
CD8 (nontargeting control; shNT), which have previously been
published.31,32 BCL-W protein expression was examined by western
blotting at 48 and 96 hours after shRNA induction, and was found
to be efficiently knocked down in all 3 cell lines (Figure 4A;
quantification of representative western blots at 96 hours compared
to shNT control: Raji-BL: ;88% knockdown, Ramos-BL: ;70%
knockdown, HT: ;98% knockdown). Cell viability (Figure 4B) and
proliferation (Figure 4C) were monitored during shRNA induction.
Additionally, we measured the response of these cells to the BH3-
mimetic drugs ABT-737 (BCL-2/BCL-XL/BCL-W inhibitor) and
S63845 (MCL-1 inhibitor; note different doses were used depend-
ing on the cell line examined) following 72 hours of shRNA induction
(Figure 4D). In all tests, no differences in cell viability, proliferation,
or sensitivity to BH3-mimetic drugs were observed between
BCL-W knockdown cells and cells expressing the nontargeting
shRNA. Collectively, the results obtained from shRNA knockdown
of BCL-W were consistent with our CRISPR/CAS9-mediated gene
disruption studies, and suggest that anticancer therapies targeting
BCL-W would be ineffective at killing the examined human BL- and
DLBCL-derived cell lines.
Discussion
The development of new BH3-mimetic drugs continues to be an
area of great research focus due to the ongoing success of the
BCL-2 inhibitor venetoclax for cancer therapy, and the promising
preclinical evaluation of MCL-1 inhibitors, resulting in their entry into
clinical trials for certain blood cancers in 2018.15,20,41 BCL-XL
inhibitors have also been developed but progression in the clinic
has been hampered by on-target toxicity to platelets.42 Attention is
Figure 4. (continued) SD for 3 independent experiments. (C) Cell proliferation following doxycycline induction of shNT or shBCL-W expression over 96 hours. Error bars
represent the SD for 3 independent experiments. (D) Viability of BCL-W knockdown (shBCL-W) and control (shNT) cells following treatment with the indicated doses of
BH3-mimetic drugs for 24 hours: S63845 (MCL-1 inhibitor), ABT-737 (BCL-2/BCL-XL/BCL-W inhibitor). Experiments were performed on cells following 72 hours of shRNA
induction. Cell viability was measured by the proportion of cells that were Annexin V and DAPI double-negative by flow cytometry, and results were normalized to
a DMSO-treated control sample. Knockdown of BCL-W did not sensitize any cell lines to ABT-737 or S63845 (Student t test, P . .05 for all). Error bars represent the SD for
3 independent experiments.
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now shifting to address the therapeutic potential of targeting less
well-studied BCL-2 family prosurvival members, such as BCL-W
and BFL-1/A1. BCL-W is a particularly attractive anticancer target
because loss of BCL-W has no effect on the normal healthy cells
of mice, besides male sterility, suggesting it would be relatively
well-tolerated by patients.2,3 We sought to examine the role of
BCL-W in BLs and DLBCLs to ascertain whether BCL-W may be
an effective drug target for the treatment of these malignancies,
and ultimately whether BH3-mimetic drugs targeting BCL-W
could have an effect in the clinic for the treatment of patients with
these lymphomas.
We characterized BCL-2 family member expression in 6 human
B-cell lymphoma–derived cell lines, detecting BCL-W protein by
western blotting in only 4 of the lymphoma lines. Furthermore, qRT-
PCR analysis showed that BCL-W mRNA was expressed at
relatively low levels in these cell lines compared with the other
prosurvival membersMCL-1 and BCL-X. Interestingly, treatment of
the parental cell lines with a range of BH3-mimetic drugs revealed
that the MCL-1 inhibitor S63845 was the most effective at
inducing cell death in 5 of the 6 lymphoma cell lines examined,
suggesting a primary dependence on MCL-1 for sustained growth,
as has been shown previously for BLs.36,43 To look directly at a role
for BCL-W in sustained survival and growth of these lymphoma
cell lines, we used CRISPR/CAS9 gene editing to successfully
generate 3 DLBCL cell lines (HT, SUDHL-4, and U2932) and 1 BL
cell line (Ramos-BL) exhibiting substantially reduced expression of
BCL-W, as well as numerous single-cell–derived clones com-
pletely lacking BCL-W protein. In addition, we repeated these
experiments in 2 of the previously listed cell lines, along with an
additional cell line Raji-BL, using shRNA to knock down BCL-W
expression. We found that loss of BCL-W expression by gene
editing or shRNA did not lead to apoptosis in the human BL cell
lines Ramos-BL and Raji-BL, nor did we observe any effect of BCL-
W loss on the growth and survival of the 3 DLBCL-derived cell lines
examined.
It has been shown that BH3-mimetic drugs can be more effective at
killing certain types of cancers when used together in combinations44,45;
therefore, we investigated this in the context of targeting BCL-W
alongside other BCL-2 prosurvival proteins. We found that
reduced or even complete loss of BCL-W expression did not
increase the sensitivity of any of the lymphoma cell lines tested to
treatment with BH3-mimetic drugs targeting the prosurvival
proteins BCL-2, MCL-1, or BCL-XL individually, or targeting both
BCL-XL and BCL-2 (and any remaining BCL-W) using ABT-737.
Therefore, we anticipate therapeutic targeting of BCL-W alone
would be ineffective at killing these B-cell lymphoma–derived cell
lines and furthermore, it would not be expected to sensitize the
tumor cells to BH3-mimetic drugs targeting other prosurvival BCL-
2 family members.
In this study, we interrogated the expression of BCL-W at the RNA
and protein levels using RNA knockdown, gene editing, and
pharmacological approaches to disrupt BCL-W expression. From
all experiments, our results indicate that BCL-W is dispensable for
the sustained survival and growth of select human DLBCL- and BL-
derived cell lines, despite its reported overexpression in patient
samples and cell lines.25,26 Although the expression levels of
prosurvival BCL-2 family members are generally thought to be good
indicators of susceptibility to specific BH3-mimetic drugs,28,46 we
found that this was not always the case. For example, U2932
cells predominantly express MCL1 by qRT-PCR, but show only
negligible sensitivity to single-agent treatment with S63845.
Thus, the high levels of BCL-W gene expression reported in
some DLBCL patient samples may not necessarily indicate that
these malignant cells are dependent on BCL-W for survival.
Collectively, our results suggest that the development of new
BH3-mimetic drugs that specifically target BCL-W will not be
effective for all incidences of these B-cell lymphomas. However,
it remains possible that BCL-W may play a role in the develop-
ment of B-cell lymphomas and furthermore may be an effective
therapeutic target in other human malignancies that we have not
examined here.
Acknowledgments
The authors thank all members of the Molecular Genetics of Cancer
Division at The Walter and Eliza Hall Institute (WEHI) for their
support and advice; S. Monard and his team at the WEHI Flow
Cytometry Unit; M. Herold and the MAGnetic Expansion Control
(MAGEC) laboratory at WEHI for CRISPR/CAS9 and shRNA
constructs; G. Lessene, C. White, and D. Huang for supplying
aliquots of BH3-mimetic drugs; andR. Anderson and L.O’Reilly for
antibodies. Next-generation sequencing was performed by
Stephen Wilcox at the Ian Potter Centre for Genomics within
the Walter and Eliza Hall Institute for Medical Research (Parkville,
VIC, Australia).
This work was supported by funding from the Victorian Cancer
Agency Fellowship (MCRF 17028) (G.L.K.), Cancer Council
Victoria, grants-in-aid #1086157 and #1147328 (G.L.K.), the
National Health and Medical Research Council (grant 1086291)
(G.L.K.), Program grant 101671 (A.S.), Fellowship 1020363 (A.S.),
Leukaemia Foundation Australia grant (G.L.K. and A.S.), Leukaemia
and Lymphoma Society (grant 7001-13) (A.S.), the estate of
Anthony (Toni) RedstoneOAM, TheCraig Perkins Cancer Research
Foundation, and operational infrastructure grants through the
Australian Government National Health and Medical Research
Council Independent Research Institutes Infrastructure Support
Scheme and the Victorian State Government Operational In-
frastructure Support.
Authorship
Contribution: S.T.D., A.S., and G.L.K. conceived and designed the
research; S.T.D., C.C., and L.T. performed the experiments; J.-n.G.,
P.L., A.C.D., and G.S.T. provided reagents; S.T.D., A.S., and G.L.K.
analyzed data and interpreted results; S.T.D. drafted themanuscript;
and A.S. and G.L.K. edited and revised the manuscript.
Conflict-of-interest disclosure: TheWalter and Eliza Hall Institute
receives milestone and royalty payments related to venetoclax, and
employees (S.T.D., C.C., L.T., J.-n.G., A.S., and G.L.K.) may be eli-
gible for benefits related to these payments. The laboratory of A.S.
receives research funding from Servier. The remaining authors de-
clare no competing financial interests.
ORCID profiles: S.T.D., 0000-0002-1946-5161; P.L., 0000-
0002-9285-3259; A.C.D., 0000-0002-1909-7047.
Correspondence: Gemma L. Kelly, The Walter and Eliza Hall
Institute, 1G Royal Parade, Parkville, VIC 3052, Australia; e-mail:
gkelly@wehi.edu.au.
364 DIEPSTRATEN et al 28 JANUARY 2020 x VOLUME 4, NUMBER 2
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/2/356/1632656/advancesadv2019000541.pdf by U
N
IVER
SITY O
F BIR
M
IN
G
H
AM
 -U
SD
 AC
C
O
U
N
T user on 28 February 2020
References
1. Gibson L, Holmgreen SP, Huang DCS, et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene. 1996;13(4):665-675.
2. Print CG, Loveland KL, Gibson L, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci
USA. 1998;95(21):12424-12431.
3. Ross AJ, Waymire KG, Moss JE, et al. Testicular degeneration in Bclw-deficient mice. Nat Genet. 1998;18(3):251-256.
4. Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer.
2016;16(2):99-109.
5. Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25(1):27-36.
6. Hockings C, Anwari K, Ninnis RL, et al. Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for
Bak versus Bax. Cell Death Dis. 2015;6(4):e1735.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
8. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905.
9. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood.
2007;109(1):271-280.
10. Zantl N, Weirich G, Zall H, et al. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to
apoptosis resistance. Oncogene. 2007;26(49):7038-7048.
11. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma
cells. Blood. 2002;100(1):194-199.
12. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99(6):1885-1893.
13. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;
4(3):362-375.
14. Arnosti DN, Merino A, Reinberg D, Schaffner W. Oct-2 facilitates functional preinitiation complex assembly and is continuously required at the promoter
for multiple rounds of transcription. EMBO J. 1993;12(1):157-166.
15. Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: Blazing the trail for new cancer medicines. Cancer Cell. 2018;
34(6):879-891.
16. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):
311-322.
17. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre,
open-label, phase 2 study. Lancet Oncol. 2016;17(6):768-778.
18. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously
untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216-228.
19. Lin TL, Strickland SA, Fiedler W, et al Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age $65 with acute
myelogenous leukemia [abstract]. J Clin Oncol. 2016;34(15_suppl). Abstract 7007.
20. Xiang W, Yang C-Y, Bai L. MCL-1 inhibition in cancer treatment. OncoTargets Ther. 2018;11:7301-7314.
21. Tao ZF, Hasvold L, Wang L, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACSMedChem Lett. 2014;5(10):1088-1093.
22. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
23. Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase
1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-1159.
24. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of
navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-496.
25. Adams CM, Kim AS, Mitra R, Choi JK, Gong JZ, Eischen CM. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J Clin Invest. 2017;
127(2):635-650.
26. Adams CM, Mitra R, Gong JZ, Eischen CM. Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW. Clin Cancer Res. 2017;23(22):
7119-7129.
27. Adams CM, Mitra R, Vogel AN, Liu J, Gong JZ, Eischen CM. Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma [published
online ahead of print 21 October 2019]. Leukemia. doi:10.1038/s41375-019-0611-9.
28. Soderquist RS, Crawford L, Liu E, et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic
sensitivity. Nat Commun. 2018;9(1):3513.
29. Aubrey BJ, Kelly GL, Kueh AJ, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting
mutations in vivo. Cell Reports. 2015;10(8):1422-1432.
30. Gong J-N, Khong T, Segal D, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;
128(14):1834-1844.
28 JANUARY 2020 x VOLUME 4, NUMBER 2 BCL-W IS NOT ESSENTIAL FOR LYMPHOMA GROWTH 365
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/2/356/1632656/advancesadv2019000541.pdf by U
N
IVER
SITY O
F BIR
M
IN
G
H
AM
 -U
SD
 AC
C
O
U
N
T user on 28 February 2020
31. Zou H, Lai Y, Zhao X, et al. Regulation of mammalian target of rapamycin complex 1 by Bcl-2 and Bcl-XL proteins. J Biol Chem. 2013;288(40):
28824-28830.
32. Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in
transgenic rats. Proc Natl Acad Sci USA. 2008;105(47):18507-18512.
33. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent
developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629.
34. Klanova M, Andera L, Brazina J, et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent
subgroups of diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22(5):1138-1149.
35. Stolz C, Hess G, Ha¨hnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood.
2008;112(8):3312-3321.
36. Kelly GL, Grabow S, Glaser SP, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.Genes
Dev. 2014;28(1):58-70.
37. Wang K, Chen X, Zhan Y, et al. miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of
BCL-W. Tumour Biol. 2015;36(9):6875-6882.
38. Lu C, Xie Z, Peng Q. MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am
J Cancer Res. 2017;7(9):1863-1873.
39. Yang T, Thakur A, Chen T, et al. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour
Biol. 2015;36(6):4357-4365.
40. Yang X, Yin J, Yu J, et al. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep. 2012;27(1):250-257.
41. Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination
with established therapies. Cancer Discov. 2018;8(12):1582-1597.
42. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173-1186.
43. Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477-482.
44. Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute
myeloid leukemia. Leukemia. 2019;33(4):905-917.
45. Lee EF, Harris TJ, Tran S, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10(5):342.
46. Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective
antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132-1144.
366 DIEPSTRATEN et al 28 JANUARY 2020 x VOLUME 4, NUMBER 2
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/2/356/1632656/advancesadv2019000541.pdf by U
N
IVER
SITY O
F BIR
M
IN
G
H
AM
 -U
SD
 AC
C
O
U
N
T user on 28 February 2020
